Peptides / Longevity and mitochondria

Synthetic analog · 4 amino acids · 461.5 Da

Livagen (KEDA)

Livagen is a short synthetic peptide (Lys-Glu-Asp-Ala) from the Khavinson bioregulator family, and no approval as a drug was found. Its studies are mostly in lab cells, with a few in animals, on markers of aging and the liver. PepBank shows 27 results on Livagen from animal and lab studies. No study in people has reported results yet. Data as of 2026-10-30.

Also known as KEDA, Livagen, Livagen peptide, Lys-Glu-Asp-Ala

4 amino acids, from first to lastKEDA

Evidence level: Animal and lab studies onlyNo study in people has results. ClinicalTrials.gov lists no trial.

Results in people

0% of 27 results

Results in animals

7% of 27 results

Results in lab cells

93% of 27 results

From computer models

0% of 27 results

Overview

Livagen (KEDA) at a glance

What it is	Synthetic analog, 4 amino acids
Approval	Regulatory status not recorded
In sport	Status unknown
Studies	13 studies with results. 11 of them gave Livagen, with 27 results. 2 in animals25 in lab cells
Clinical trials	None registered
Community use	Community interest in liver and cellular aging research

The science

What is Livagen?

Synthetic Lys-Glu-Asp-Ala peptide from the Khavinson bioregulator family.

Amino acids in one chain

Livagen (KEDA) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 4 amino acidsFrom the first amino acid to the last

+K1−E−DA

Darker means more water-repelling+ and − show charge in the body

Structure

Livagen (KEDA) is a synthetic analog of 4 amino acids, with no ring, no changed amino acids.

Formula

C₁₈H₃₁N₅O₉

Molecular weight

461.5 g/mol

CAS number

433257-50-2

Development

Highest phase: no known clinical development.

Identifiers

PubChem 87919683

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Lys-Glu-Asp-Ala-OH

InChIKey
IKVDKWACACMDLR-BJDJZHNGSA-N

SMILES
C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N

See charge, composition and 3D structure on the Scientific page

The evidence

What Livagen studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Animal and lab studies onlyNo study in people has results. ClinicalTrials.gov lists no trial.

Cells, genes and aging

10 results · 10 lab

In cells from old donors, Livagen induced chromosome 1 pericentromeric structural chromatin decondensation. Bulletin of experimental biology and medicine, 2004

Liver

4 results · 4 lab

In lab tests, Livagen stimulated structural and functional stability in liver cell populations. Advances in gerontology = Uspekhi gerontologii, 2002

Metabolism and nutrition

2 results · 2 lab

In cells from rats of different ages, Livagen increased protein synthesis, with the greatest effect in old animals' cells. Izvestiia Akademii nauk. Seriia biologicheskaia, 2001

Key Livagen studies

Studies in people come first, then studies in animals and in the lab.

Animals
[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]
Timofeeva et al. 2005 · Advances in gerontology = Uspekhi gerontologii · cited by 1
3 results
Lab cells
Tissue-specific effects of peptides
Khavinson et al. 2001 · Bulletin of experimental biology and medicine · cited by 3
1 result
Lab cells
[Functional morphology of an organotypic liver culture exposed to the peptide livagen]
Riadnova et al. 2002 · Advances in gerontology = Uspekhi gerontologii · cited by 0
4 results
Lab cells
Effects of Livagen peptide on chromatin activation in lymphocytes from old people
Khavinson et al. 2002 · Bulletin of experimental biology and medicine · cited by 3
3 results
Lab cells
Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals
Lezhava et al. 2007 · Annals of the New York Academy of Sciences · cited by 2
2 results

All 13 Livagen (KEDA) studies

Livagen clinical trials

ClinicalTrials.gov lists no trial of Livagen. A trial under another name may exist.

Status and safety

Is Livagen approved?

FDA

United States

Status unknown

Status unknown.

EMA

European Union

Status unknown

Status unknown.

WADA

Sport

Not recorded

Status unknown.

Regulatory status not recorded. Status unknown.

Laws and labels change, so check the regulator for the current status.

Livagen side effects and safety

PepBank has no safety result from studies of Livagen yet. That does not mean Livagen is safe.

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The guide describes liver and cellular aging research. It reports a use pattern, without proof of safety or benefit.

Reported routines and cautions

What people use it for

Community interest in liver and cellular aging researchS1

Reported regimens

Regimens that community sources report for Livagen. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Community interest in liver and cellular aging research	subcutaneous injection	1 mg per dose	once daily	10 to 20 days	Single non-vendor guide. The underlying community reports were not independently verified.	S1

Community sources

S1Livagen community guide (opens in a new tab)vialguide.com

Gaps

This is one secondary guide. It does not identify the underlying community reports. Other regimens exist in the guide. No official medicine label was established. Product purity and actual use were not independently tested.

Questions and more

Ask a question about Livagen

The answer links to every study it uses.

What does the evidence say about Livagen?Is Livagen tested in people?Compare with NMN (nicotinamide mononucleotide)Compare with AICAR (acadesine)

Sources

Database: PepBank data for Livagen (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about Livagen

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Livagen (KEDA)

Also known as KEDA, Livagen, Livagen peptide, Lys-Glu-Asp-Ala

What it is

Synthetic analog, 4 amino acids

Approval

Regulatory status not recorded

In sport

Status unknown

Studies

13 studies with results. 11 of them gave Livagen, with 27 results.
2 in animals25 in lab cells

Clinical trials

None registered

Community use

Community interest in liver and cellular aging research

Context

Route

Amount

How often

How long

Agreement

Sources

Community interest in liver and cellular aging research

subcutaneous injection

1 mg per dose

once daily

10 to 20 days

Single non-vendor guide. The underlying community reports were not independently verified.

Livagen (KEDA)

Livagen (KEDA) at a glance

What is Livagen?

Livagen (KEDA) structure and chemistry